Key result
Coronary flow rate was lower in statin-naïve patients with dyslipidemia and diabetes despite morphologically normal arteries.
Why the study?
Dynamic CCTA was implemented to estimate the coronary flow rate in morphologically normal coronary arteries and identify factors affecting it.
Does dyslipidemia or diabetes reduce dynamic CCTA-estimated coronary flow rate in morphologically normal coronary arteries?
Observational (n=95)
Does dyslipidemia or diabetes reduce dynamic CCTA-estimated coronary flow rate in morphologically normal coronary arteries?
Dynamic CCTA reveals that statin-naïve dyslipidemia and diabetes are associated with reduced coronary flow rates even in the absence of obstructive coronary plaque, suggesting early microvascular or endothelial dysfunction.
Answers are grounded in this paper and cite their sources.
Lower coronary flow in statin-naïve dyslipidemia or diabetes despite normal arteries; hypothesis-generating for early microvascular dysfunction, needs prospective trials.
Rationale and Objectives: In this study, we implemented dynamic coronary CT angiography (CCTA) in order to estimate the coronary flow rate in morphologically normal coronary arteries as well as to identify factors affecting the coronary flow rate. Materials and Methods: We retrospectively enrolled 95 consecutively presenting patients without stenosis or plaque in their major coronary arteries on CCTA conducted with a 320-detector scanner (mean age, 57 years; 43 % men). Time-attenuation curves of the distal sites of the major coronary arteries and the aortic root were extracted from dynamic CCTA data. Coronary flow rate, an indicator of coronary blood flow, was calculated via a convolution-integration method integrating the two curves. Patients with dyslipidemia were divided according to the presence or absence of familial hypercholesterolemia (FH) as well as according to the receipt of statin therapy. Results: We found that the coronary flow rate was statistically significantly lower in statin-naïve patients with dyslipidemia (n = 27, 0.56 ± 0.10) than in patients without dyslipidemia (n = 32, 0.64 ± 0.10, p = 0.0013). In FH (n = 26), the coronary flow rate was statistically significantly lower in statin-naïve patients (n = 7, 0.65 ± 0.08) than in those taking statins (n = 19, 0.72 ± 0.10, p = 0.0221). Coronary flow rate likewise exhibited a statistically significant negative correlation with hemoglobin A1c (Pearson r, -0.437; p = 0.0003), but no correlation with other coronary risk factors. The coronary flow rate was statistically significantly lower in patients with diabetes (n = 14, 0.55 ± 0.10) than in those without diabetes (n = 81, 0.61 ± 0.11, p = 0.0461). Conclusion: We found a reduction in coronary flow rate in patients with statin-naive dyslipidemia and diabetes, even within morphologically normal coronary arteries.
No takes yet. Share an insight, caveat, or question.
Izoe et al. (2022) conducted an observational in Non-obstructive, plaque-free coronary arteries (n=95). Statin-naïve dyslipidemia vs. Without dyslipidemia was evaluated on Coronary flow rate (p=0.0013). Coronary flow rate was lower in statin-naïve patients with dyslipidemia and diabetes despite morphologically normal arteries.
Synapse has enriched 10 related papers. Consider them for comparative context: